Urine test may spare bladder cancer patients from frequent scopes
NCT ID NCT07511517
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a urine test called BladMetrix to see if it can detect bladder cancer returning after surgery. 500 adults with non-muscle invasive bladder cancer will provide urine samples during routine follow-up visits over 2 years. The test's accuracy will be compared to standard cystoscopy (camera exam) and urine cytology. If it works well, it could reduce the need for invasive camera exams.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BladMetrix urine test
What this could lead to
If successful, this urine test could reduce the need for frequent camera exams (cystoscopies) and allow more personalized follow-up schedules for people with bladder cancer.
What could go wrong
This is an observational study, not a treatment trial. The test is still being compared to standard methods, and it may not be accurate enough to replace cystoscopy. Results are early and need further validation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY BLADDER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akershus University Hospital (Ahus)
Lørenskog, Norway
-
Haukeland University Hospital
Bergen, Norway
-
Oslo University Hospital - Aker
Oslo, Norway
-
St. Olavs Hospital - Trondheim University Hospital
Trondheim, Norway
-
University Hospital of North Norway (UNN)
Tromsø, Norway
-
Vestfold Hospital Trust (SiV)
Tønsberg, Norway